A New Hope for the Patients of Non‐Alcoholic Steatohepatitis: FDA Gives Green Signal for Resmetirom Use

A New Hope for the Patients of Non‐Alcoholic Steatohepatitis: FDA Gives Green Signal for Resmetirom Use

ABSTRACT Background and Aims Non‐Alcoholic Steatohepatitis (NASH), a severe form of Non‐Alcoholic Fatty Liver Disease (NAFLD), is characterized by inflammation and fibrosis in the liver, often progressing to cirrhosis and hepatocellular carcinoma. Despite its rising prevalence and significant diseas...

Full description

Saved in:
Bibliographic Details
Main Authors: Abdul Haseeb Hasan, Muhammad Ali Abid, Muhammad Hafi Abid, Laiba Suhail, Abubakar Nazir
Format: Article
Language:English
Published: Wiley 2025-01-01
Series:Health Science Reports
Subjects:
cirrhosis
NAFLD
NASH
non‐alcoholic steatohepatitis
resmetirom
rezdiffra
Online Access:https://doi.org/10.1002/hsr2.70394
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items